Epigral Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 06/10 00:29

Epigral (NSE:EPIGRAL) Full Year 2025 Results

Key Financial Results

  • Revenue: ₹25.5b (up 32% from FY 2024).
  • Net income: ₹3.58b (up 83% from FY 2024).
  • Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue.
  • EPS: ₹84.68 (up from ₹47.14 in FY 2024).
revenue-and-expenses-breakdown
NSEI:EPIGRAL Revenue and Expenses Breakdown June 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Epigral EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%.

The primary driver behind last 12 months revenue was the India segment contributing a total revenue of ₹23.5b (92% of total revenue). Notably, cost of sales worth ₹14.8b amounted to 58% of total revenue thereby underscoring the impact on earnings.Explore how EPIGRAL's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India.

Performance of the Indian Chemicals industry.

The company's shares are up 3.3% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Epigral's balance sheet and an in-depth analysis of the company's financial position.